Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Aronex out-licenses antibody-toxin complex

Jan. 15, 1997

Treatment begun in pivotal trial of Coulter radioimmunopharmaceutical

Dec. 24, 1996

Positive clinical results reported for MDX-22 in AML patients

Dec. 12, 1996

Positive IDEC-C2B8 phase III trial results announced

Dec. 11, 1996

Medarex bispecific antibody enters phase II in colon cancer patients

Dec. 9, 1996

Sandoz claims MAbs against Lewis group antigens for therapeutic use

Nov. 25, 1996

IDEC to present final pivotal data on IDEC-C2B8

Nov. 22, 1996

NCI sponsors clinical trials with Therion's prostate cancer vaccine

Nov. 22, 1996

First filing for Imutec's Virulizin

Nov. 21, 1996

Final phase II data presented for Biomira's therapeutic cancer vaccine

Nov. 15, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...